July 19, 2024

Bright Green Stumbles: Financial Woes Cast Shadow on Cannabis Research Aspirations

MMJ International Holdings (MMJIH), a company at the forefront of pharmaceutical cannabis research, has filed Investigational New Drug (IND) applications with the FDA to conduct clinical trials for Multiple Sclerosis (MS) and Huntington’s Disease (HD). MMJ has also developed proprietary THC and CBD capsules derived from marijuana extracts, making them the only company with a final-dose THC and CBD medicine ready for human trials.

However, progress is hampered by the DEA’s sluggish processing of MMJ’s application to cultivate cannabis for research purposes. This bureaucratic hurdle stands in stark contrast to the FDA’s receptiveness to MMJ’s advancements.

Political Tug-of-War and Rescheduling Efforts

Despite Health and Human Services (HHS) Secretary Xavier Becerra’s agreement to reschedule cannabis to Schedule III, acknowledging its medical value, the DEA remains the final arbiter. This political tug-of-war highlights the disconnect between scientific evidence and federal policy. MMJ BioPharma Labs has already secured a critical DEA Schedule I analytical lab license, demonstrating their commitment to navigating the complex regulatory landscape.

Legal Action and Scientific Hurdles

MMJ BioPharma Cultivation has filed a lawsuit against the DEA to expedite their application, emphasizing the urgency of facilitating clinical trials for MS and HD patients. Dr. Elio Mariani, MMJ’s Chief Scientist, underscores their adherence to FDA guidelines, ensuring drug reproducibility and safety. However, the FDA’s stringent review process remains a hurdle due to the inherent variability of cannabis’s chemical composition.

Standardization Challenges and Financial Woes

Lawmakers like Rep. Andy Harris (R-Md.) have expressed concerns about replicating cannabis chemistry for clinical trials, mirroring the issues faced by other DEA registrants like Bright Green Corp. (BGXX). Bright Green, despite years of development, has yet to secure a DEA quota or produce any products. Their financial woes, including a multi-million dollar deficit and negative working capital, further illustrate the precarious position of companies operating in this nascent industry.

MMJ Forges Ahead

While facing headwinds, MMJ remains the only company with FDA-approved formulations ready for clinical trials. Their dedication to advancing research for debilitating diseases like MS and HD underscores the potential of cannabis as a medicine. Clear policy direction and streamlined regulations are crucial to unlock the full therapeutic potential of cannabis and deliver new treatment options to patients.


On this website we use first or third-party tools that store small files (cookie) on your device. Cookies are normally used to allow the site to run properly (technical cookies), to generate navigation usage reports (statistics cookies) and to suitable advertise our services/products (profiling cookies). We can directly use technical cookies, but you have the right to choose whether or not to enable statistical and profiling cookies. Enabling these cookies, you help us to offer you a better experience.